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Abstract
Background: Xpert MTB/RIF (‘‘Xpert’’) is a molecular test for detection of Mycobacterium tuberculosis (MTB) in sputum.
Performance characteristics have been established for its use during passive tuberculosis (TB) case detection in symptomatic
TB suspects, but Xpert performance has not been assessed in other settings. Objectives were to determine Xpert
performance and costs in the context of a TB prevalence survey.
Methodology/Principal Findings: This was a diagnostic sub-study of a TB prevalence survey conducted in gold mining
companies in South Africa. Sputa (one per participant) were tested using smear microscopy, liquid culture (reference
comparator), and Xpert. Costs were collected using an ingredients approach and analyzed using a public health program
perspective. 6893 participants provided a sputum specimen. 187/6893 (2.7%) were positive for MTB in culture, 144/6893
(2.1%) were positive for MTB by Xpert, and 91/6893 (1.3%) were positive for acid fast bacilli by microsocopy. Sensitivity,
specificity, positive predictive value, and negative predictive value for detection of MTB by Xpert were 62.6% (95%
confidence interval [CI] 55.2, 69.5), 99.6% (99.4, 99.7), 81.3% (73.9, 87.3), and 98.9 (98.6, 98.8); agreement between Xpert and
culture was 98.5% (98.2, 98.8). Sensitivity of microscopy was 17.6% (12.5, 23.9). When individuals with a history of TB
treatment were excluded from the analysis, Xpert specificity was 99.8 (99.7, 99.9) and PPV was 90.6 (83.3, 95.4) for detection
of MTB. For the testing scenario of 7000 specimens with 2.7% of specimens culture positive for MTB, costs were $165,690 for
Xpert and $115,360 for the package of microscopy plus culture.
Conclusion: In the context of a TB prevalence survey, the Xpert diagnostic yield was substantially higher than that of
microscopy yet lower than that of liquid culture. Xpert may be useful as a sole test for TB case detection in prevalence
surveys, particularly in settings lacking capacity for liquid culture.
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Introduction
Tuberculosis (TB) prevalence surveys have been used to assess
the performance of TB control programs, provide information for
strategic planning, and assess trends of disease burden over time
[1,2,3,4]. TB prevalence surveys are increasingly being used to
measure the impact of large-scale interventions such as isoniazid
preventive therapy and enhanced TB case finding [5,6,7,8].
Historically in prevalence surveys, pulmonary TB case detection
has been based on microbiological evaluation using sputum smear
microscopy; symptom assessment and chest radiographs are
sometimes used as initial screens in order to identify individuals
who subsequently undergo microbiological evaluations in order to
maximize efficiency and minimize laboratory costs [2]. Few
prevalence surveys have included mycobacterial culture, which is
considered the gold standard for individual patient-based TB
diagnosis but has substantial infrastructure and labor requirements
and is prone to contamination [4]. Sputum smear-based surveys
are problematic due to the low sensitivity of smear especially in
HIV-related TB [9–11] and the inability of smear to provide
information about drug resistance, an understanding of which is
critical for TB control. Mycobacterial culture of sputum is
complex and relatively expensive at the laboratory level, and
depends on sputum transport conditions that retain M. tuberculosis
(MTB) viability without promoting growth of contaminating
organisms.
Xpert MTB/RIF (Cepheid, Sunnyvale, CA) is an integrated
specimen processing and nucleic acid amplification-based test for
detection of MTB and rifampin resistance-conferring mutations
directly from sputum [12]. As used for passive TB case detection in
respiratory symptomatic adults in the context of a clinical
validation trial and a large multisite demonstration study in which
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overall TB prevalences among tested participants were 49% and
25%, respectively, Xpert MTB/RIF (‘‘Xpert’’) had sensitivities of
approximately 98% for smear-positive/culture positive TB and
72.5% to 76.9% for smear-negative/culture-positive disease, with
specificity of approximately 99% [13,14]. It is worth pointing out
that these studies did not include anyone on TB treatment.
Several Xpert characteristics besides relatively high sensitivity
make it attractive for use in population-based surveys. First, unlike
culture-based tests, Xpert does not require viable bacilli, thereby
potentially making specimen storage and transport conditions less
demanding. Second, the risk of specimen-to-specimen cross
contamination with MTB appears to be very low for the closed
cartridge Xpert test, based on data from a research laboratory
[15]. Third, the automated performance of almost all Xpert
testing steps within the closed cartridge manufactured using
quality controls would be expected to lessen lab-to-lab variability,
which can be problematic in large prevalence surveys using
culture. Fourth, Xpert provides information about rifampicin
resistance, which is highly associated with multidrug-resistance
and poor treatment outcomes using conventional TB treatment
regimens [13,14]. However, the latter potential attribute must be
tempered by reports of false-positive rifampicin resistance results
by Xpert [14,16,17,18]. The total Xpert run time is about 2 hours,
substantially less than that for cultures. Finally, for Xpert
procedures the laboratory biosafety risks are limited and therefore
extensive biocontainment infrastructure is not required [13,19].
We incorporated Xpert testing into a TB prevalence survey in
which MGIT culture and smear microscopy were already being
performed on all sputa. The overall study goal was to determine
the performance of Xpert when used for TB case ascertainment in
the context of a population-based TB prevalence survey.
Methods
Design and Setting
This was a diagnostic sub-study of a cross-sectional TB
prevalence survey conducted in gold mining companies in South
Africa. The parent prevalence survey was conducted to measure a
secondary endpoint of the ‘Thibela TB’ study, a cluster
randomized trial of the impact of community-wide TB preventive
therapy on the burden of TB in a setting of high HIV prevalence
[5]. This diagnostic sub-study was conducted in 12 of the 15
clusters (mine shafts) participating in the Thibela TB study.
Participants
Participants were recruited based on a consecutive sample of
employees attending occupational health services for their annual
fitness examination from April 2010 to May 2011. Demographic
information and targeted information about current and previous
TB treatment and HIV were obtained from participants through
interviews with study staff. HIV testing was not a component of
the ‘Thibela TB’ study or this diagnostic sub-study. Participants
were provided with information about how to expectorate a deep
sputum specimen. One spontaneously expectorated respiratory
specimen was collected from each participant; any specimen
produced was tested. Sputa were briefly stored at 4uC, and
transported to the study laboratory within 24 hours of collection.
Laboratory Methods
All tests were conducted by a single reference laboratory with
quality-assured smear microscopy and culture. Sputa were
decontaminated using N-acetyl-L-cysteine-NaOH, with final
[NaOH] of 1% [20]. After centrifugation, the pellet was
suspended in approximately 1.5 ml of phosphate buffer pH6.8.
A Ziehl-Neelsen-stained smear of the decontaminated sediment
was examined by light microscopy and graded according to WHO
criteria [21]. A 0.5 ml portion of the sediment was inoculated into
the BACTEC MGIT 960 system (BD Diagnostic Systems, Sparks,
MD) using Mycobacterial Growth Indicator Tubes (MGITs, BD
Diagnostic Systems). Positive cultures were confirmed as myco-
bacteria using Ziehl-Neelsen staining, and as MTB using an anti
MPB64 monoclonal antibody assay (Capilia TB-Neo, TAUNS
Laboratories, Numazu, Japan) test. Indirect phenotypic drug
susceptibility testing was performed using the MGIT SIRE system
(BD Diagnostic Systems) only for isolates for which the sputum
had been rifampicin resistant by Xpert.
Xpert MTB/RIF tests were conducted and interpreted accord-
ing to the manufacturer’s recommendations. Xpert MTB/RIF kit
sample reagent was added in a 3:1 (volume:volume) ratio to 0.5 ml
of the decontaminated sputum pellet, incubated at room
temperature for 15 minutes, and 2 ml of this mixture was added
to an Xpert MTB/RIF cartridge. A 4-module GeneXpert
(Cepheid) instrument with automated readout was used. An Xpert
test was considered ‘‘failed’’ if a definitive reading of MTB
detected or MTB not detected could not be obtained on two test
attempts from the same decontaminated sputum pellet, or on one
attempt if there was insufficient remaining specimen volume for a
second attempt.
Statistical Analysis
Laboratory data were single entered and source verified into a
database and discrepancies were checked against the source data.
Demographic data were captured directly onto a database at the
participant interview. Diagnostic yield was defined as the (number
of positive tests/total # tests)6100. Xpert sensitivity, specificity,
and predictive values were calculated using MGIT culture results
as the reference standard; specimens were excluded from these
analyses if the MGIT result was ‘‘contaminated’’ (since either the
presence or absence of MTB could not be established) or if the
Xpert result was ‘‘failed’’. A culture was considered positive if M.
tuberculosis (identified to the species level) was detected; cultures
with no growth or with growth of a mycobacterium other than M.
tuberculosis were considered negative for analysis purposes. Com-
parisons of proportions were performed using McNemar’s chi-
square and Fisher’s exact tests for paired and unpaired data,
respectively, and 95% confidence intervals (CIs) were calculated
using the binomial exact method. Odds ratios using logistic
regression were used to assess the association between previous
and current TB with ‘‘false positive’’ detection of MTB by Xpert,
where ‘‘false positive’’ by Xpert was defined as a test result of
positive for MTB by Xpert yet negative for MTB by MGIT.
Economic Evaluation
Laboratory costs associated with conducting Xpert testing were
compared with those associated with using a package of smear
microscopy with MGIT culture along with organism identification
and MGIT-based phenotypic drug susceptibility testing (DST)
using the SIRE system (Becton Dickinson). Costs were collected at
the National Health Laboratory Service (NHLS) reference TB
laboratory in Johannesburg, South Africa. An ‘‘ingredients’’
approach was used that involved multiplying the quantity of
inputs used by their unit prices. Costs were considered from the
time of specimen receipt at the laboratory through reporting of test
results. Costs associated with sputum collection and transportation
were not included. The amount of staff time, consumable supplies,
and equipment quantities utilized for each test were determined
through direct observation of testing procedures, and included
costs associated with laboratory quality control procedures.
Xpert MTB/RIF in a TB Prevalence Survey
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Overhead laboratory costs included indirect labor costs, office and
laboratory supplies, furniture, and physical infrastructure (build-
ing, utilities, maintenance, medical waste disposal). Overhead costs
were allocated for each test system based on the volume of testing
and physical infrastructure utilized by each diagnostic system.
Costs were gathered using detailed laboratory budget records.
Capital item costs and maintenance costs were estimated from
manufacturer or distributor quotations and NHLS laboratory
invoices; capital item costs were annualized over items’ useful
lifespans. Building rental costs and utilities were estimated based
on 2011 commercial real estate pricing in Johannesburg. Costs for
Xpert instrument and reagent kits reflected the reduced pricing
structure negotiated by the Foundation for Innovative New
Diagnostics for the South African public sector. For the base-
case we assumed that the lab was running at 100% capacity (8–
12 hours/day for five days/week). Costs for microscopy were
based on Ziehl-Neelsen staining and light microscopy. Costs for
staff time during the ,120 minute Xpert running time were not
included. A currency conversion rate of 6.978 South African rand
per 1.00 U.S. dollar was used – this was the average conversion
rate for 2011 at the time of the final data analysis.
Ethics
This study was approved by ethics boards of the University of
the KwaZulu Natal, the London School of Hygiene and Tropical
Medicine, and the Johns Hopkins University School of Medicine.
All participants provided written or witnessed verbal informed
consent. Verbal informed consent was allowed in order to not
exclude illiterate participants from this minimal risk study; the
verbal consent process was witnessed by an impartial witness. The
verbal consent process was explicitly approved by the ethics boards
listed above. Principals expressed in the Declaration of Helsinki
were followed during the conduct of this research.
Results
During the study period 7346 individuals were enrolled. Fifteen
were unable or unwilling to provide a sputum specimen, resulting
in 7331 collected sputa. Among those sputa were 438 for which
one or more of the three protocol-specified tests (smear
microscopy, MGIT culture, Xpert) were not performed due to
either administrative error or lack of Xpert cartridges. Therefore
the main analysis set was comprised of 6893 sputa from 6893
consecutive participants. Participant characteristics are shown in
Table 1. Almost all were black males, reflecting the composition of
the gold mining workforce. Of those who reported ever having had
an HIV test, 14.5% (602/4156) reported their HIV status as
positive. At the time of the study interview and sputum collection,
60/6893 individuals (0.9%) reported that they were currently on
treatment for active TB (‘current TB treatment’), 833/6893
(12.1%) reported a prior history of treatment for active TB (‘prior
TB treatment’), and 5994 (87.0%) reported no current or prior TB
treatment.
Figure 1 and Table 2 show the results of MGIT and Xpert tests
for all 6893 specimens. By MGIT testing 187 (2.7%) were positive
for MTB, 389 (5.6%) were positive only for growth of non-
tuberculosis mycobacteria, 249 (3.6%) were contaminated, and
6068 (88.0%) were negative for any growth. By Xpert testing, 144
(2.1%) were positive for MTB, 6726 (97.6%) were negative for
MTB, and 23 (0.3%) failed to yield a result. Xpert quantitation
results for the 144 sputa in which that test detected M. tuberculosis
were ‘‘high’’ for 6 (4.2%), ‘‘medium’’ for 10 (6.9%), ‘‘low’’ for 45
(31.3%), and ‘‘very low’’ for 83 (57.6%). The MTB diagnostic
yield of MGIT (187/6893; 2.7%) was higher than that for Xpert
(144/6893, 2.1%; p= 0.017) and either of these methods had a
higher yield than smear microscopy (91/6893; 1.3%; p= 0.001 vs.
Xpert yield).
Table 3 shows Xpert performance characteristics overall and
stratified by smear microscopy status, using MGIT as the reference
comparator. Overall, 6621 sputa had an interpretable result for
MGIT culture and Xpert; excluded from this analysis were 249
sputa with a MGIT final result of ‘‘contaminated’’ and 23 sputa
with an Xpert final result of ‘‘failed’’. Xpert sensitivity was 62.6%
(95% CI 55.2, 69.5), specificity 99.6% (99.4, 99.7), positive
predictive value (PPV) 81.3% (73.9, 87.3), negative predictive
value (NPV) 98.9% (98.6, 99.2), and agreement 98.5% (98.2,
98.8). Xpert sensitivity and PPV were higher for smear-positive
specimens than for smear-negative specimens (sensitivity 32/33
[97.0%] for smear-positives vs. 85/154 [55.2%] for smear
negatives, p,0.001; PPV 32/33 [97.0%] for smear-positives vs.
85/111 [76.6%] for smear-negatives, p = 0.01). Specificity, NPV,
and agreement were similar by smear status. For detection of
MTB, the sensitivity of smear microscopy was 33/187 (17.6%;
12.5, 23.9) vs. Xpert sensitivity of 62.6%; p#0.001).
Xpert was positive for MTB in 27 specimens that were negative
for MTB growth (and not contaminated) by MGIT culture: 25
had no growth in MGIT culture and 2 had growth of a
mycobacterium determined not to be MTB by MPB64 antigen
testing of the cultured bacteria. Among these 27 specimens, 8
(29.6%) were from participants with current TB treatment, 9
(33.3%) were from participants with prior TB treatment, and 10
(37.0%) were from participants without current or prior TB
treatment. Xpert quantification was ‘‘low’’ in 6/27 (22.2%) and
‘‘very low’’ in 21/27 (77.8%). Median months from self-reported
TB diagnosis to study sputum collection were 2.5 (range 1–4) and
9 (range 1–43) for participants with current TB treatment and
participants with prior TB treatment, respectively. A ‘‘false
positive’’ Xpert result was strongly associated with current TB
treatment (OR 92.1; 34.9, 243.0); prior TB treatment was also
associated with a false positive Xpert test (Table 4).
To further explore the impact of current or prior TB on Xpert
performance, we calculated Xpert performance stratified by TB
history (Table 5). Among participants without current or prior TB
treatment, Xpert specificity was exceedingly high at 99.8% (5599/
5609), and PPV reached 90.6% (96/106). Specificity and PPV
were lowest among participants with current TB treatment
(specificity 85.2% [46/54] and PPV 33.3% [4/12]). For Xpert
and MGIT culture considered separately, we explored test
sensitivity for detection of prevalent TB if participants with
‘‘current TB’’ were considered as prevalent TB cases in addition to
participants whose sputum MGIT culture grew MTB. Among the
resulting 241 TB cases, MGIT detected 187/241 (77.6%; 95% CI
71.8, 82.7) and Xpert detected 125/241 (51.9%, 95% CI 45.4,
58.3; p#0.001).
Among 144 specimens with MTB detected by Xpert, rifampicin
resistance was detected for 7/144 (4.9%), not detected for 134/
144 (93.1%), and indeterminate for 3/144 (2.1%). Among the
seven specimens that were rifampicin resistant by Xpert, five were
rifampicin resistant by MGIT phenotypic testing, and two had no
growth in primary MGIT culture so phenotypic susceptibility
testing could not be performed.
Costs for equipment and consumables are shown in Table S1.
Under the base scenario, the cost per sputum specimen tested was
$23.67 for Xpert and $15.55 for the package of smear microscopy
plus MGIT culture for MTB detection (Table 6). For the testing
scenario of 7000 tested specimens (among which 2.7% of cultures
were positive for MTB and subsequently subjected to phenotypic
drug susceptibility testing [DST]), the total cost for an Xpert
Xpert MTB/RIF in a TB Prevalence Survey
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Table 1. Baseline characteristics of 6893 study participants.
Characteristic N %
Male sex 6469 93.9
Race Black/African 6758 98.0
White/European 107 1.6
Mixed race 28 0.4
Median age (IQR) in years 43 (34, 49)
HIV status by participant verbal report ‘Positive’ 602 8.7
‘Negative’ 3455 50.1
‘Don’t know’ 99 1.4
Missinga 2737 39.7
Symptoms Cough #2 weeks 91 1.3
Cough .2 weeks 138 2.0
Night sweats 226 3.3
Weight loss 106 1.5
Current and prior TB treatment Current TB treatmentb 60 0.9
Prior TB treatmentc 833 12.1
No history of current or prior TB treatment 5994 87.0
Unknown 6 0.09
Abbreviation: IQR, interquartile range.
aof these, 2613 reported never having had an HIV test, 122 had an HIV test but were not willing to disclose results, and 2 had missing data.
bon treatment for active TB when the study sputum specimen was obtained.
cprior treatment for active TB but not on TB treatment when the study sputum specimen was obtained.
doi:10.1371/journal.pone.0043307.t001
Figure 1. Flow diagram of Xpert and MGIT testing results.
doi:10.1371/journal.pone.0043307.g001
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testing strategy was $165,690 and for the package of smear/MGIT
culture/MGIT DST was $115,360 (difference of $50,330).
Discussion
The ‘Thibela TB’ final prevalence survey offered a unique
opportunity to evaluate Xpert performance in a population-based
TB survey, as the infrastructure was in place for the survey.
Moreover, MGIT testing was performed for each specimen,
thereby allowing direct comparison between Xpert and MGIT.
We reasoned that Xpert performance characteristics, especially
PPV, might be different when implemented in a scenario in which
relatively few individuals have TB disease (e.g. a prevalence
survey, some settings of active/enhanced TB case finding, and
passive detection of TB cases in low TB prevalence settings such as
the U.S.) versus when applied for passive detection in high TB
burden settings. We sought to establish Xpert performance
characteristics in this highly structured setting in which MGIT
culture was performed in order to inform the potential use of
Xpert in future TB prevalence surveys and other initiatives in
which TB disease prevalence is relatively low.
We found that the proportion of tests yielding a non-informative
result was lower for Xpert than for MGIT, although the overall
TB diagnostic yield of Xpert (2.1%) was lower than that for MGIT
(2.7%). Xpert sensitivity, using MGIT as the reference compar-
ator, was 62.6% overall, which is lower than that reported for
Xpert used for passive case detection in symptomatic pulmonary
TB suspects in validation and demonstration studies [13,14], but
similar to that reported by Lawn among consecutive HIV-infected
adults enrolling in an ART clinic whose sputum was tested by
Xpert regardless of symptoms [22].The lower overall sensitivity in
our study was driven by the generally low sputum bacillary burden
among TB cases in our prevalence survey – among culture-
positive TB cases only 17.6% were smear microscopy positive.
However we found that the sensitivity of Xpert in smear positive,
culture positive TB cases was 97.0%, which is similar to that
reported by others [13,14]. The exceedingly low observed
sensitivity of smear microscopy highlights the inadequacy of this
test, at least in the context of a TB prevalence survey in an HIV
prevalent setting. NTM were identified in just over 5% of
specimens by MGIT culture, whereas, as expected, Xpert was
negative in almost all of those. We did not assess the clinical
significance of NTM isolates in individual study participants.
However, the ability of liquid culture methods to facilitate
diagnosis of lung disease caused by NTM and, by contrast, the
inability of Xpert to provide such diagnostic information, would
make liquid culture advantageous in some clinical circumstances.
As a general principle, the positive predictive value of a test with
imperfect specificity is typically adversely affected in scenarios of
low disease prevalence since a relatively large proportion of
positive tests will be ‘‘false positives’’. In a recent WHO report,
Xpert PPV was calculated to be 74% and 65% under TB
prevalence scenarios of 3% and 2%, respectively, when an Xpert
specificity estimate of 99% was used [23]. However, in our study in
which observed TB prevalence as assessed by MGIT was 2.7%,
Table 2. Results for MGIT culture and Xpert MTB/RIF for 6893
sputum specimens.
MGIT
MTB NTM Negative
Contam-
inated Total
Xpert MTB 117 2 25 0 144
Negative 70 383 6024 249 6726
Failed 0 4 19 0 23*
Total 187 389 6068 249* 6893
*p,0.001 for comparison of proportions of contaminated MGIT cultures (249/
6893 [3.6%]) vs. invalid Xpert tests (23/6893 [0.3%]).
doi:10.1371/journal.pone.0043307.t002
Table 3. Performance characteristics of the Xpert MTB/RIF test overall, and stratified by smear microscopy status, using MGIT
culture as the reference standard.
Overall Smear-positive Smear-negative
Total N=6621a Total N=87b Total N=6534
Xpert sensitivity N/N 117/187 32/33 85/154
% (95% CI) 62.6 (55.2, 69.5) 97.0 (84.2, 99.9) 55.2 (47.0, 63.2)
Xpert specificity N/N 6407/6434 53/54c 6354/6380
% (95% CI) 99.6 (99.4, 99.7) 98.2 (90.1, 100.0) 99.6 (99.4, 99.7)
Xpert PPV N/N 117/144 32/33 85/111
% (95% CI) 81.3 (73.9, 87.3) 97.0 (84.2, 99.9) 76.6 (67.6, 84.1)
Xpert NPV N/N 6407/6477 53/54 6354/6423
% (95% CI) 98.9 (98.6, 99.2) 98.2 (90.1, 100.0) 98.9 (98.6, 99.2)
Agreement between Xpert and
MGIT
N/N 6524/6621 85/87 6439/6534
% (95% CI) 98.5 (98.2, 98.8) 97.7 (91.9, 99.7) 98.6 (98.2, 98.8)
Abbreviations: CI, confidence interval; MGIT, Mycobacteria Growth Indicator Tube;
PPV, positive predictive value; NPV, negative predictive value.
aExcluded from the analyses were 249 specimens that were contaminated in MGIT culture and 23 specimens that had a final result of failed on Xpert MTB/RIF testing.
bsensitivity of smear microscopy for detection of MTB, using MGIT as reference standard, was 33/187 (17.6%, [95%CI 12.5, 23.9]) vs. Xpert sensitivity of 62.6% overall
(p#0.001).
cThese 54 specimens were culture-negative for M. tuberculosis. For 11/54, a non-tuberculous mycobacterium was isolated from culture. For 43/54 the culture was
negative for any mycobacterial growth; among these 43 specimens, 32 were smear grade scanty.
doi:10.1371/journal.pone.0043307.t003
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the Xpert PPV was 81.3%, reflecting a relatively low number of
false positive Xpert tests. Furthermore, the demonstrated associ-
ation of current TB treatment and the results pattern of Xpert
positive for MTB but MGIT negative for MTB is compatible with
a scenario in which active TB (with MTB organisms) was present
and the MGIT was falsely negative, presumably due to antibiotic-
mediated suppression of bacterial growth. In a secondary analyses
from which participants with current or prior TB were excluded,
Xpert PPV was just over 90%, representing only 10 false positives
among 5764 tested specimens. Xpert attributes that might
contribute to low percentages of falsely positive results include its
analytical specificity based on the molecular probe designs, its
closed cartridge system that minimizes specimen-to-specimen
cross-contamination, and its automated readout that minimizes
user interpretation errors. False-positive cultures for MTB are not
rare – one literature review identified false-positive cultures in 13
(93%) of 14 studies that assessed .100 patients, and the median
false-positive percentage was 3.1% [24].
Molecular tests for TB can detect nucleic acids from non-viable
bacilli, and in our study a test result of Xpert positive for MTB but
MGIT negative for MTB was strongly associated with current TB.
The implications of a positive test result arising from non-viable
organisms will vary based on testing circumstances. In our study
participants were queried about current TB treatment – those on
current TB treatment are arguably a subset of prevalent TB cases,
and Xpert detected a higher proportion of them than did MGIT.
A limitation of our study is that Xpert tests were performed on
decontaminated sputum pellets rather than on raw sputum. As
MGIT culture result was the stated gold standard for TB diagnosis
in the context of the ‘Thibela TB’ prevalence survey, every effort
was made to ensure that sample handling was optimal for MGIT
culture. Therefore raw sputum was not split, a process that can
result in nonequivalent fractions. In a large multisite trial of Xpert
there was no difference in yield from raw sputum versus
decontaminated pellets [13]. Another limitation is that only one
respiratory specimen was obtained per participant; testing of
additional specimens by culture might have helped to resolve
discrepancies in which the Xpert was positive yet the culture was
negative. Finally, the relatively low number of TB cases identified
in our prevalence survey did not allow us to meaningfully assess
Table 4. Factors associated with ‘‘false positive’’ detection of M. tuberculosis by Xpert MTB/RIF.
False-positive Xpert result for detection of
M. tuberculosis Odds Ratio
N (row %) 95% CIb
No current or prior TB treatment 10/5764a (0.2) 1
Current TB treatment 8/58 (13.8) 92.1 (34.9, 243.0)
Prior but not current TB treatment 9/797 (1.1) 6.6 (2.7, 16.2)
Abbreviations: CI, confidence interval.
afour participants who reported not being on current TB treatment but did not know if they had ever been on TB treatment were coded as ‘‘no current or prior TB
treatment’’.
boverall P-value ,0.001.
doi:10.1371/journal.pone.0043307.t004
Table 5. Performance characteristics of the Xpert MTB/RIF test stratified by participant TB treatment status, using MGIT culture as
the reference standarda.
No current or prior TB
treatment Current TB treatment
Prior but not current TB
treatment
N=5764b N=58 N=797
Xpert sensitivity N/N 96/155 4/4 17/28
% (95% CI) 61.9 (53.8, 69.6) 100 (39.8, 100.0) 60.7 (40.6, 78.5)
Xpert specificity N/N 5599/5609 46/54 760/769
% (95% CI) 99.8 (99.7, 99.9) 85.2 (72.9, 93.4) 98.8 (97.8, 99.5)
Xpert PPV N/N 96/106 4/12 17/26
% (95% CI) 90.6 (83.3, 95.4) 33.3 (9.9, 65.1) 65.4 (44.3, 82.8)
Xpert NPV N/N 5599/5658 46/46 760/771
% (95% CI) 99.0 (98.7, 99.2) 100.0 (92.3, 100.0) 98.6 (97.5, 99.3)
Agreement between Xpert and
MGIT
N/N 5695/5764 50/58 777/797
% (95% CI) 98.8 (98.5, 99.1) 86.2 (74.6, 93.9) 97.5 (96.2, 98.5)
Abbreviations: CI, confidence interval; MGIT, Mycobacteria Growth Indicator Tube; PPV, positive predictive value; NPV, negative predictive value.
aExcluded from the analyses were 249 specimens that were contaminated in MGIT culture, 23 specimens that had a final result of failed on Xpert MTB/RIF testing, and 2
specimens from participants for whom data on TB treatment status were missing.
bfour participants who reported not being on current TB treatment but did not know if they had ever been on TB treatment were coded as ‘‘no current or prior TB
treatment’’.
doi:10.1371/journal.pone.0043307.t005
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Xpert performance characteristics for detection of rifampicin
resistance. False-positive rifampicin resistance results from Xpert
testing have been reported, and any imperfection in assay
specificity would be expected to result in a substantially reduced
positive predictive value (for rifampicin resistance) in a setting of
low MDR-TB prevalence [14,16,17,18].
We determined the laboratory costs of a testing program using
Xpert alone versus a program combining smear microscopy with
MGIT culture and MGIT-based DST for MTB-positive cultures.
The cost for the Xpert program was 44% greater than that for the
microscopy/MGIT program. Xpert cartridge unit costs accounted
for just over 70% of Xpert per test cost, and therefore the
laboratory costs for an Xpert testing program would be expected
to be reduced with declining cartridge costs. Our per test cost
results are strikingly similar to those reported by Vassall and
sourced from a demonstration study of Xpert use including in
South Africa [25]. For the South African study sites, Vassall
reported Xpert costs per test of $22.00 and $25.90 assuming Xpert
cartridge unit costs of $15.50 and $19.40, respectively; we found
an Xpert per test cost of $23.67 given an actual Xpert cartridge
unit cost of $16.80. Cost per tested specimen for smear+MGIT
culture was $16.82 in the Vassall study versus $15.55 in our study.
Our costing analysis incorporated several assumptions that might
not apply to future Xpert testing programs. For example, we
assumed that a biosafety cabinet was required for Xpert testing,
and that Xpert testing was conducted by research staff at a higher
pay grade than routine service laboratory staff conducting MGIT
testing. While these assumptions applied to our MGIT-based
‘Thibela TB’ prevalence survey laboratory testing program, these
aspects are not strictly required for conducting Xpert testing.
In summary, in the context of a MGIT-based TB prevalence
survey, Xpert sensitivity was substantially higher than that of
smear microscopy but lower than that of MGIT culture. Xpert
detected a subset of prevalent TB cases (namely individuals on TB
treatment when the prevalence survey sputum was obtain) not
detected by MGIT, and the proportion of Xpert tests that were
non-informative was lower than that for MGIT. We conclude that
Xpert has promise for use as a sole testing strategy in the context of
TB prevalence surveys and other initiatives in which prevalence
and pre-test probability of TB disease are relatively low. In the
context of a TB prevalence survey, Xpert sensitivity less than that
of MGIT might be counterbalanced by Xpert ease of use.
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